在多发性硬化症管理中调节肠道微生物群:对当前干预措施的系统审查
Anthi Tsogka1, Dimitrios K Kitsos1, Konstantina Stavrogianni1,2
1Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
Journal of clinical medicine
|December 23, 2023
概括
肠道微生物群干预措施,如饮食,益生菌,FMT和间歇性禁食,显示出对管理多发性硬化症 (MS) 症状的承诺. 这些方法对MS患者的临床结果,炎症和生活质量产生积极影响.
科学领域:
- 神经免疫学 神经免疫学
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
- 人们越来越认识到肠道微生物组在多发性硬化症的发病和进展中的作用.
- 针对肠道微生物群的干预措施正在被探索为MS的新型治疗策略.
研究的目的:
- 审查最近关于肠道微生物群干预多发性硬化症 (MS) 的临床研究.
- 评估MS患者的饮食方案,益生菌,便微生物群移植 (FMT) 和间歇性禁食 (IF) 的临床和自身免疫影响.
主要方法:
- 2011年至2023年间发表的13项临床研究的系统审查.
- 研究调查了MS患者的干预措施,包括特殊饮食,益生菌补充剂,FMT和IF.
- 分析的重点是这些干预措施对临床参数和自身免疫标志物的影响.
主要成果:
- 饮食干预改善了MS复发率,EDSS分数,疲劳和代谢特征.
- 益生菌对疲劳,EDSS和炎症有好处,转向一种抗炎症特征.
- 便微生物群移植 (FMT) 和间歇性禁食 (IF) 表明EDSS,情绪状态和生活质量的临床改善.
结论:
- 通过饮食,益生菌,FMT和IF调节肠道微生物群,为MS的各种临床方面提供了显著的好处.
- 这些干预措施对MS患者的残疾分数,疲劳,情绪和整体生活质量产生积极影响.
- 肠道微生物组和MS之间的复杂相互作用突出了潜在的治疗途径.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Irritable Bowel Syndrome III: Medical and Nursing Management
209
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
209
Irritable Bowel Syndrome I: Introduction
277
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
277


